# US 2024/0199525 A1 · SHP2-Targeting Small Molecules For Use As Anti-Cancer Agents

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199525 A1
- Document ID: US20240199525A1
- Status: Published application
- Kind: A1
- Application number: 18/511,496
- Filed: 2023-11-16
- Published: 2024-06-20
- Earliest claimed: 2022-11-17
- Assignees: West Virginia University Board of Governors on behalf of West Virginia University
- Applicants: West Virginia University Board of Governors on behalf of West Virginia University
- Inventors: Yehenew Agazie
- Web page: https://patentgrep.com/patent/US20240199525A1

## CPC

- C07C 65/24: polycyclic
- A61P 35/00: Antineoplastic agents
- C07C 59/64: containing six-membered aromatic rings
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound of the formula: wherein R1 is a hydrogen or a COOH, R2 is a hydrogen or a COOH, R3 is a hydrogen or a COOH, R4 is one selected from the group consisting of H, COOH, and CH2COOH, and R5 is one selected from the group consisting of H, COOH, and CH2COOH. The present invention provides a compound having the formula: wherein R is COOH or CH2COOH. Pharmaceutical compositions comprising one of these compounds and at least one of an acceptable pharmaceutical carrier, are provided. Methods of treating a patient having cancer are provided.

## Claims

### Claim 1

A compound of the formula:
wherein R1 is a hydrogen or a COOH, R2 is a hydrogen or a COOH, R3 is a hydrogen or a COOH, R4 is selected from one of the group consisting of H, COOH, and CH2COOH, and R5 is selected from one of the group consisting of H, COOH, and CH2COOH.

### Claim 2 (depends on 1)

The compound of claim 1 that is a phosphotyrosyl phosphatase 2 inhibitor.

### Claim 3 (depends on 1)

The compound of claim 1 wherein R1 is COOH, and wherein R2, R3, and R4 are each H, and wherein R5 is CH2COOH.

### Claim 4 (depends on 1)

The compound of claim 1 wherein R1, R3, and R4 are each H, and wherein R2 is COOH, and wherein R5 is CH2COOH.

### Claim 5

A pharmaceutical composition comprising a compound having the formula:
wherein R1 is a hydrogen or a COOH, R2 is a hydrogen or a COOH, R3 is a hydrogen or a COOH, R4 is one selected from the group consisting of H, COOH, and CH2COOH, and R5 is one selected from the group consisting of H, COOH, and CH2COOH, and
at least one acceptable pharmaceutical carrier.

### Claim 6 (depends on 5)

The pharmaceutical composition of claim 5 including wherein said compound has the formula wherein R1 is COOH, and wherein R2, R3, and R4 are each H, and wherein R5 is CH2COOH.

### Claim 7 (depends on 5)

The pharmaceutical composition of claim 5 including wherein said compound has the formula wherein R1, R3, and R4 are each H, and wherein R2 is COOH, and wherein R5 is CH2COOH.

### Claim 8

A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of the formula:
wherein R1 is a hydrogen or a COOH, R2is a hydrogen or a COOH, R3 is a hydrogen or a COOH, R4 is selected from one of the group consisting of H, COOH, and CH2COOH, and R5 is selected from one of the group consisting of H, COOH, and CH2COOH, for treating said patient.

### Claim 9 (depends on 8)

The method of claim 8 including wherein said compound has the formula wherein R1 is COOH, and wherein R2, R3, and R4 are each H, and wherein R5 is CH2COOH.

### Claim 10 (depends on 8)

The method of claim 8 including wherein said compound has the formula wherein R1, R3, and R4 are each H, and wherein R2 is COOH, and wherein R5 is CH2COOH.

### Claim 11

A method of treating a patient having cancer comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound having the formula:
wherein R1 is a hydrogen or a COOH, R2 is a hydrogen or a COOH, R3 is a hydrogen or a COOH, R4 is one selected from the group consisting of H, COOH, and CH2COOH, and R5 is one selected from the group consisting of H, COOH, and CH2COOH, and
an acceptable pharmaceutical carrier, for treating said patient.

### Claim 12 (depends on 11)

The method of claim 11 including wherein said compound has the formula wherein R1 is COOH, and wherein R2, R3, and R4 are each H, and wherein R5 is CH2COOH.

### Claim 13 (depends on 11)

The method of claim 11 including wherein said compound has the formula wherein R1, R3, and R4 are each H, and wherein R2 is COOH, and wherein R5 is CH2COOH.

### Claim 14

A compound that is a derivative of CNBDA that is a phosphotyrosyl phosphatase 2 inhibitor.

### Claim 15

A compound of the formula 4′-(carboxymethyl)-4-(nonyloxy)-[1,1′-biphenyl]-3-carboxylic acid (BPDA2).

### Claim 16

A compound having the formula:
wherein R is COOH or CH2COOH.

### Claim 17

A pharmaceutical composition comprising a compound having the formula:
wherein R is COOH or CH2COOH, and
at least one pharmaceutically acceptable carrier.

### Claim 18

A method of treating a patient having cancer comprising administering a therapeutically effective amount of a compound of the formula:
wherein R is COOH or CH2COOH.

### Claim 19

A method of treating a patient having cancer comprising administering a therapeutically effective amount of a pharmaceutical composition comprising a compound having the formula:
wherein R is COOH or CH2COOH, and
at least one pharmaceutically acceptable carrier, for treating said patient.
